www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
336
FORMULATION ASPECTS BY APPROACHING DIFFERENT
POLYMERS OVER MATRIX TABLETS
Kailas Tarkase1*, Sandesh Bole
2*, Snehal Khatke
2, Sonal Shinde
2 and Sagar Yenare
2
1Asst. Prof. Department of Pharmaceutical Quality Assurance, Dr. Vitthalrao Vikhe Patil
Foundation’s Collage of Pharmacy, Vilad Ghat, Ahmednagar, (MS), India, 414111.
2Department of Pharmaceutical Quality Assurance, Dr. Vitthalrao Vikhe Patil Foundation’s
Collage of Pharmacy, Vilad Ghat, Ahmednagar, (MS), India, 414111.
ABSTRACT
An ideal drug delivery system should aid in the optimization I the drug
therapy by delivering an appropriate amount to the intended site at a
desired rate. An oral drug delivery system providing a uniform drug
delivery can only partly satisfy therapeutic and biopharmaceutical
needs, as it doesn’t take in to account the site specific absorption rates
within the Gastrointestinal Tract (GIT). Therefore there is a need of
developing drug delivery system that release the drug at the right time,
at a specific site and desired rate. A matrix system consists of active
and inactive ingredients that are homogeneously dispersed and mixed
together into dosage form. In this, we discuss about oral controlled
release dosage form and its various polymers used to formulate in
sustained release matrix tablet. The use of polymer in the matrix tablet
is to controlling the drug release and play important role in
formulation.
KEYWORDS: Polymer, Matrices, Drug Release, Dissolution, Diffusion, Biological factors,
Physiological factor etc.
INTRODUCTION
Tablets are offered to safe end with drug administration with appropriate method of active
pharmaceutical administration with excellent biological and physiochemical stability and
accurate dosing of a drug.
World Journal of Pharmaceutical Research SJIF Impact Factor 8.074
Volume 8, Issue 8, 336-353. Review Article ISSN 2277– 7105
Article Received on
02 May 2019,
Revised on 22 May 2019,
Accepted on 12 June 2019,
DOI: 10.20959/wjpr20198-15271
*Corresponding Author
Kailas Tarkase
Asst. Prof. Department of
Pharmaceutical Quality
Assurance, Dr. Vitthalrao
Vikhe Patil Foundation’s
Collage of Pharmacy, Vilad
Ghat, Ahmednagar, (MS),
India, 414111.
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
337
Modified release dosage forms whose drug release kinetics of time course or location are
chosen to accomplish therapeutic or convenience objective not provided by conventional or
immediate release forms.
Extended release dosage form whose drug release slowly, so that plasma concentration is
maintained at a therapeutic level for period of time.
Delayed release dosage form whose drug is now being released immediately following
administration but at a later time, E.g. Enteric coated tablet.
Prolonged release dosage form this type of dosage form indicates that the drug is provided for
absorption over a longer period of time than the from a conventional dosage form.
Sustained release dosage form this dosage form which indicated an initial release of drug
sufficient to provide a therapeutic amount dose soon after administration, and then a gradual
release over an extended period of time.
Extended Release Tablet V/S Conventional Release Tablet
Extended release tablet and capsules = Administered once or twice a day,
While conventional release tablet and capsule = Administered 3 to 4 times a day to
achieve same therapeutic effects.
For non oral rate-controlled drug delivery system = 24 hours for most Transdermal
patches from months to years.
Drawbacks Associated With Conventional Dosage Forms
1. A drug with short biological half life which needs a close succession administration is
required, so it may increase the missing of dosage forms leads to poor patient compliance.
2. The uncontrolled fluctuation of drug level may leads to either below effective range or
over the effective range.
3. Plasma concentration verses time profile of dosage form and it’s difficult to achieve the
steady state active drug level.
4. The rise and fall of drug level it may give to accumulation of adverse effects especially
for a drug having less therapeutic index.
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
338
Figure no. 1: Plasma drug concentration profiles for conventional tablet formulation, a
sustained release formulation and a zero order controlled release formulation.
Advantages of sustained release drug delivery system
1. Reduction in dosing frequency.
2. Reduced fluctuation in circulating drug levels.
3. Increased patient convenience and compliance.
4. Avoidance of night time dosing.
5. More uniform effect.
6. Maximum utilization of drug.
7. Reduction in GIT irritation and other side effects.
8. Reduction in health care cost through improved therapy.
9. Improve bioavailability of some drugs.
Disadvantages of sustained release drug delivery system
1. Decreased systemic availability in comparison to immediate release conventional dosage
form, this may be due to
Incomplete release
Increased first-pass metabolism, increased instability
Site specific absorption, pH dependent solubility, etc.
2. Poor in vitro-in vivo correlation.
3. Possibility of drug dumping.
4. Retrival of drug is difficult in case of toxicity, poisoning, or hypersensitivity reactions.
5. Higher cost of formulation.
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
339
Techniques employed in the design and fabrication of Oral Drug Delivery System
1. Dissolution controlled release
Encapsulation dissolution control
Matrix dissolution control
2. Diffusion controlled release
Reservoir devices
Matrix devices
3. Diffusion and dissolution controlled system
4. Ion-exchange resins
5. pH-independent formulations
6. Osmotically controlled release
7. Altered density formulations
Classification of Matrix Tablets
(A) Hydrophobic matrix system
In this type of matrix system the use of polymer is not essential to provide controlled drug
release, and in it the insoluble polymers are used. These ingredients include waxes, fatty
acids, and polymeric materials such as ethyl cellulose, methyl cellulose and acrylate
copolymer. The presence of insoluble ingredients in the formulations helps to maintain the
physical dimensions of hydrophobic matrix during drug release.
(B) Hydrophilic matrix system
When the release medium (i.e. water) is thermodynamically compatible with a polymer, the
solvent penetrate into the free spaces between macromolecular chains. The polymer may
undergo a relaxation process, due to the stress of the penetrate solvent, so that the polymer
chain become more flexible and the matrix swells. This allows the encapsulated drug to
diffuse more rapidly out of the matrix.
(C) Lipid matrix system
These materials manufactured by the lipoid waxes and related ingredients. Active from of
drug from the dosage form release the content such matrices followed by either diffusion or
erosion. A drug release properties are mainly depends on the absorption medium fluid
component than hydrophobic-polymers. Either Stearyl alcohol or stearic acid mixed with
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
340
carnauba wax it has been mainly applicable for release retarding polymer in sustained release
formulation of tablet.
(D) Biodegradable matrix system
These types of polymer are biodegraded either by enzymatic or non enzymatic process. It
contains the polymeric substance which is composed of monomeric linking to the other
functional group and gives unstable linkage in the backbone. Consist of the polymer which
comprised of monomers linked to one another functional groups and have unstable linkage in
the backbone. Finally the biodegradable material is excreted in the enzymatic process.
Advantages of matrix tablet
1) Maintains therapeutic concentrations over prolonged periods.
2) Reduction in toxicity by slowing drug absorption.
3) Minimize the local and systemic side effects.
4) Improvement in treatment efficacy.
5) Minimize drug accumulation.
6) Increase the stability by protecting the drug from hydrolysis or other derivative changes in
GIT.
7) Reduction in health care cost.
8) Usage of less total drug.
9) Improved patient compliance.
Disadvantages of matrix tablet
1) The remaining matrix must be removed after the drug has been released.
2) Greater dependence on GI residence time of dosage form.
3) Increased potential for first-pass metabolism.
4) Delay in onset of drug action.
5) Release rate continuously diminishes due to increased diffusion resistance and decrease in
effective areas at the diffusion front.
Drug release system of matrix tablet
Drug in the outer layer exposed to the bathing solution is dissolved first and after that diffuses
out of the matrix. This process continues interact with bathing solution and the solid drug
moving toward the interior. It allows that for this system to be diffusion controlled, the rate of
the dissolution of drug particles within the matrix must be faster than the diffusion rate of
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
341
dissolved drug leaving the matrix. Derivation of the mathematical model to describe this
system involves the following assumptions:
A pseudo-steady state is maintained during drug release.
1. The diameter of the drug particle is less than the average distance of drug diffusion
through the matrix.
2. The bathing solution provides sink condition at all times.
The majority of oral CR systems are depending on dissolution, diffusion or a combination of
both mechanisms, to generate slow release of drug into the gastrointestinal milieu.
1. Dissolution controlled systems
Drug with slow dissolution rate will demonstrate sustaining properties, since the release of
the drug will be limited by rate of dissolution. This being the case, SR preparations of drugs
could be made by decreasing their dissolution rate. This includes preparing appropriate salts
or derivatives, coating the drug with a slowly dissolving carrier.
The dissolution process at steady process state, is described by Noyes-Whitney equation,
dc/dt = KDA(Cs-C) = D/h A (Cs-C)
Where,
dc/dt = Dissolution rate
KD = Diffusion co-efficient
A = Surface area of the dissolving solid
Cs = Saturation solubility of the solid
C = Concentration of solute in bulk solution
H = Thickness of diffusion layer
Figure no. 2: Dissolution controlled matrix system.
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
342
2. Diffusion controlled systems
Basically diffusion process shows the movement of drug molecules from a region of higher
concentration to one of lower concentration. Diffusion systems are characterized by the
release rate being dependent on its diffusion through an inert membrane barrier. Usually this
barrier is an insoluble polymer.
Figure no. 3: Schematic representation of reservoir diffusion controlled drug release
reservoir.
3. Dissolution and diffusion-controlled release systems
Normally, therapeutic system will never be dependent on dissolution only or diffusion only.
In practice, the dominant mechanism for release will over shadow other process enough to
allow classification as either dissolution rate limited or diffusion controlled.
4. Ion exchange systems
These are salts of cationic or anionic exchange resins or insoluble complexes in which drug
releases results from exchange of bound drug ions that are normally present in GI fluids.
The use of ion exchange resins to prolong the effect of drugs is based on the principle that
positivity or negativity charged therapeutic molecules combined with appropriate resins yield
insoluble poly salt resonate.
5. Osmotically controlled systems
This device is fabricated as tablet that contains water soluble osmotically active drug, of that
was blended with osmotically active diluents by coating the tablet with a cellulose triacetate
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
343
barrier which functions as a semi permeable membrane. A laser is used to form a precision
orifice in the barrier, through which the drug is released due to development of osmotic
pressure difference across the membrane, when it is kept in water.
Figure no. 4: Osmotically controlled system.
6. pH independent formulations
A Buffered controlled release formulation is prepared by mixing a basic or acidic drug with
or more buffering agents, granulating with appropriate pharmaceutical excipients and coating
with GI fluid permeable film forming polymer.
Figure no. 5: Drug delivery from environmentally pH sensitive release system.
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
344
7. Altered density formulations
Several approaches have been elaborated to extend the residence time of drug delivery
system in the gastrointestinal tract.
High-density approach
Low-density approach
Release limiting parameters
1) Drug Solubility
Hydrophilic or hydrophobic and molecular weights of drug molecule are important
determinants in the release of drug from swelling and erosion controlled polymeric matrices.
2) Polymer hydration
The most important step in polymer dissolution include absorption of water in more
accessible places, rupture of polymer – polymer linkages with the simultaneous forming of
water polymer linkages, separation of polymeric chains, swelling and finally dispersion of
polymeric chain in dissolution medium.
3) Polymer viscosity
While increasing the molecular weight or viscosity of the polymer and excipients in the
matrix formulation increases the gel layer viscosity and thus slows drug dissolution. The
greater the viscosity of the gel, the more resistant the gel is to dilution and erosion, thus
controlling drug dissolution.
4) Polymer concentration
An increase in polymer concentration causes an increase in the viscosity of gel as well as
formation of gel layer with a longer diffusion path.
5) Surface area and Volume
Both the in-vivo and in-vitro rate of drug release is observed to be dependent on Surface area
of the dosage form.
6) Diluents effect
The effect of diluents or fillers depends on the nature of diluents. Water soluble diluents like
lactose increases in drug release rate and release mechanism is also shifted towards Fickian
diffusion; also the insoluble diluents like dicalcium phosphate reduce the Fickian diffusion
and increases the relaxation (erosion) rate of matrix. Because water soluble fillers in matrices
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
345
stimulate the water penetration in to inner part of matrix, due to increase in hydrophilicity of
the system, causing rapid diffusion of drug, leads to increased drug release rate.
7) Additive
The effect of adding non polymeric excipients to a polymeric matrix has been increases in the
release rate of hydro soluble active principles. These increases in release rate would be
marked if the excipients are soluble like lactose and less important if the excipients are
insoluble like dicalcium phosphate.
Drug properties relevant to sustained release formulation
The formulation of sustained release drug delivery systems, consider the some criteria such as
the route of administration, type of drug delivery system, what disease to be treated, the
patient, the duration of treatment and the characteristics of the drug those above mentioned
factor should be considered. The pharmaceutical interest to research scientist for designing of
the delivery system the following properties could be considered in the development of
dosage form. These properties can be classified by –
A. Biological properties
By definition, biological properties will be those that result from Pharmacokinetic studies
such as absorption, distribution, metabolism and excretion of drug and those resulting from
pharmacological experimental study.
B. Physicochemical properties
By definition, physicochemical properties of the drug like can be determined from in vitro
study.
Biological and Physiochemical properties having the greater importance in the design of the
drug in the delivery system and in the body. But there is no distinction between these two
categories because the biological properties of a drug as like a function of its
physicochemical properties.
Biological factors influencing oral sustained-release dosage form design
A) Absorption
Since the purpose of forming a SR product is to place control on the delivery system, it is
necessary that the rate of release is much slower than the rate of absorption. If we presume
that the transit time of most drugs in the absorptive areas of the GI tract is about 8-12 hours,
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
346
the maximum half-life for absorption should be approximately 3-4 hours; otherwise, the
device will pass out of the potential absorptive region before drug release is complete. One
method to provide sustaining mechanism of delivery for compounds tries to maintain them
within the stomach. These methods have been developed as a consequence of the observation
that co-administration results in sustaining effect.
B) Distribution
The distribution of active ingredient into the body tissue and extra vascular spaces in the
body is an important parameter for drug elimination kinetics model. Some parameters are
using to give idea about distribution of drug. Apparent volume of active component is high it
will influence the elimination of dosage form and not suitable for making sustained release
tablet. The term apparent volume of distribution of a drug is mostly used to explain the
distribution, including bound to the body system. The total apartment volume of distribution
of a drug at steady state will be calculated by given equation.
Vdss = [(K12 + K21) / K21] Vp
Where,
Vdss = Apparent volume of distribution at steady state level
K12 = Drug from central to peripheral compartment
K21 = Drug from peripheral to central compartment
Vp = Volume of central compartment
C) Metabolism
Drugs those are significantly metabolized before absorption, either in the lumen or the tissue
of the intestine, can show reduced bioavailability from slower-releasing dosage form.
Hence criteria for the drug to be used for formulating SR dosage form is,
Drug should have low half-life (<5 hrs)
Drug should be freely soluble in water
Drug should have larger therapeutic window
Drug should be absorbed throughout the GIT.
D) Biological half life
The usual goal of an oral SR product is to maintain therapeutic blood levels over an extended
period of time. To achieve this, drug must enter the circulation at approximately the same rate
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
347
at which it is eliminated. The elimination rate is quantitavely described by the half life (t1/2).
Each drug has its own characteristics elimination rate, which is the sum of all elimination
processes, including metabolism, urinary excretion and all over processes that permanently
remove drug from the blood stream. Therapeutic compounds with short half-life are generally
are excellent candidate for SR formulations, as this can dosing frequency.
E) Protein binding
The Pharmacological response of drug depends on unbound drug concentration drug rather
than total concentration and all drug bound to some extent to plasma and or tissue proteins.
Proteins binding of drug play a significant role in its therapeutic effect regardless the type of
dosage form as extensive binding to plasma increase biological half-life and thus sometimes
SR drug delivery system is not required for this type of drug.
F) Side effects
The incidence of side effect of a drug is depends on its therapeutic concentration level in
blood. It can remedy by the drug concentration level is controlled at which timing that drug
exists in blood after administration. Toxic effect of a drug is expected above the maximum
effective range level and fall in the therapeutic effect if a drug below the level of minimum
effective range. So the above problem we can solve by making sustained release preparation.
G) Margin of safety
Therapeutic index of a drug is very important for either sustained or controlled release
delivery system. Its value only desired the margin of safety. Therapeutic index value it has
been longer means excellent for preparation of sustained release tablet. Narrow therapeutic
index of some drug precise to release the active content in therapeutic safe and effective
range.
Therapeutic index = TD50/ED50
Where,
TD50 = Median toxic dose ED50 = Median effective dose
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
348
Physicochemical factors influencing oral sustained-release dosage form design
A) Dose Size
In general, a single dose of 0.5-1.0 gm is considered maximal for a conventional dosage
form. This also holds for sustained release dosage form. Compounds that require dosing size
can sometimes be given in multiple amounts or formulated into liquid systems.
B) Ionization, pka and aqueous solubility
Most drugs are weak acids or bases. Since the unchanged form of a drug preferential
permeates across lipid membranes, it is important to note the relationship between the pka of
the compound and the absorptive environment. Unfortunately, the situation is made more
complex by the fact that the drug’s aqueous solubility will generally be decreased by
conversion to unchanged to unchanged form. These dosage forms must function in an
environment of changing pH, the stomach being acidic and the small intestine more neutral,
the effect of pH on the release process must be defined.
C) Partition Coefficient
When a drug is administered to the GI tract, it must cross a variety of biological membranes
to produce a therapeutic effect in another area of the body. It is common to consider that
these membranes are lipidic; therefore the partition coefficient of oil-soluble drugs becomes
important in determining the effectiveness of membrane barrier penetration. Compounds
which are lipophilic in nature having high partition coefficient are poorly aqueous soluble
and it retain in the lipophilic tissue for the longer time. In case of compounds with very low
partition coefficient, it is very difficult for them to penetrate the membrane, resulting in poor
bioavailability.
D) Drug stability
Orally administered drugs can be subject to the both acid-base hydrolysis and enzymatic
degradation. Degradation will proceed at a reduced rate for drugs in solid state; therefore, this
is the preferred composition of delivery for problem cases. For the dosage forms that are
unstable in stomach, systems that prolong delivery over entire course of transit in the GI tract
are beneficial; this is also true for systems that delay release until the dosage form reaches the
small intestine. Compounds that are unstable in small intestine may demonstrate decreased
bioavailability when administered from a sustaining dosage form. This is because more drugs
is delivered in small intestine and hence, is subject to degradation. Propentheline and
Probanthine are representative example of such drugs.
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
349
Evaluation of tablets
1) Characterization of Tablets
a) Tablet dimensions
The diameter, thickness of five randomly selected tablets per batch was determined using
Vernier Calliper.
b) Hardness
Tablet hardness has been defined as the required force for breaking a tablet in a diametric
compression test. A tablet was placed between two anvils of hardness tester, force was
applied to the anvils, and the crushing strength that causes the tablet to break was recorded in
kg/cm2, while hardness tested using Monsanto hardness tester.
c) Organoleptic Characters of tablet
In which Taste, Odour, Color, Shape of tablet is noted. It is the preliminary test for IPQC of
tablet.
d) Friability
Tablets require certain amount of capacity or hardness and resistance to adhere mechanical
shock of handling in manufacturing, packaging, and shipping. The friability should be not
more than 1%. A pre-weighed sample (20 tablets) were placed in the friabilator, and operated
for 100 revolutions, then again weighed the tablets and % friability was calculated using the
formula,
F = (1- ) x 100
Where,
Wo = Weight of tablet before test
W = Weight of tablet after test
e) Weight Variation Test
Twenty tablets were selected randomly and then weighed these tablets individually. The
average weight of 20 tablets was calculated. Individual weights of the tablets were compared
with the average weights of the tablets.
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
350
f) Drug Content
To evaluate tablets ability for efficacy, the amount of drug per tablet needs to be monitored
from tablet to tablet, and batch to batch. To perform the test, 10 tablets were crushed using
mortar pestle. Quantity equivalent to 10 mg of drug was dissolved in 100 ml phosphate buffer
pH 6.8, filtered and diluted up to 50μg/ml, and analyzed spectrophotometrically at 225.0 nm.
The concentration of drug was determined by using of standard calibration curve.
2) Swelling Index
a) In this weighed matrix tablet (n=3) was kept in a Petri plate containing phosphate buffer of
pH 6.8.
b) Phosphate Buffer pH 6.8
Dissolve 28.80 gm of Disodium Hydrogen Phosphate & 11.45 gm of Potassium Dihydrogen
Phosphate in sufficient amount of water & finally adjust the pH by using sufficient amount of
0.1N NaOH solutions.
c) Final the weight of each tablet is calculated at an interval of 15, 30, 45 & 60 min of
interval, and % weight increased in the tablet was calculated.
Swelling Index
3) In vitro Drug Release Study
The in vitro dissolution study of formulated Venlafaxine matrix tablets were carried out using
USP apparatus Type-II (Paddle) in 900 ml of phosphate buffer solution (pH 6.8) at 37°C ±
0.5°C at a rotational speed 50 rpm. After each hr starting the test, 2 ml sample of dissolution
medium were withdrawn and analyzed spectrophotometrically at 225.0 nm by using
Shimadzu-1700 UV/visible spectrophotometer. An equal volume of freshly prepared
dissolution medium, maintained at the same temperature, was added after withdrawing each
sample to maintain the volume. The absorbance values were transformed to concentration by
reference calibration curve to a standard calibration curve obtained experimentally.
Drug selection criteria for oral sustained release drug delivery systems
The biopharmaceutical evaluation of a drug for potential used in controlled release drug
delivery system requires knowledge as follows,
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
351
Table no. 1: Pharmacokinetic parameters for drug selection.
Parameter Comment
Elimination half life Preferably between 0.5 and 8 hr
Total clearance Should not be dose dependent
Elimination rate constant Required for design
Apparent volume of distribution Vd The larger Vd and MEC, the larger will be
the required dose size.
Absolute bioavailability Should be 75% or more
Intrinsic absorption rate Must be greater than release rate
Toxic concentration
Apart the values of MTC and MEC, safer
the dosage form. Also suitable for drugs
with very short half-life.
Table no. 2: Physical parameters for drug selection.
Parameter Preferred value
Molecular weight/ size < 1000
Solubility > 0.1 mg/ml for pH 1 to pH 7.8
Apparent partition coefficient High
Absorption mechanism Diffusion
General absorbability From all GI segments
Release Should not be influenced by pH and enzymes
Key attributes for a successful SR hydrophilic matrix include
1) Fast hydration of surface polymer and gel formation (To prevent burst release of soluble
to highly soluble drugs)
2) Uniform distribution of polymer in the drug matrix. (To give consistent swelling /erosion
intra and inter tablet batch)
3) Sufficient polymer concentration on the tablet surface as well as inside the tablet to
prevent pre mature tablet disintegration (Extremely crucial to prevent dose dumping)
4) Smaller particle size of polymer (In order to have uniform distribution within the tablet
and also to hydrate faster due to high surface area)
Drugs formulated under matrix tablet
Propranolol (Anti-hypertensive)
Saxagliptin (Anti-diabetic)
Minocycline (Anti-biotic)
Ibuprofen (Anti-inflammatory)
Metformin (Anti-diabetic)
Aceclofenac (Anti -inflammatory)
Aspirin (Anti- inflammatory)
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
352
Enalprilmaleate (ACE inhibitor)
Indomethacin (Anti-inflammatory)
Metoprolol (Anti-hypertensive)
Losartan Potassium (Anti-hypertensive)
Metaprolol (Anti-hypertensive)
REFERENCES
1. The Indian Pharmacopoeia. Vol-I, II and III, the Controller of Publication, New Delhi,
2007; 63-65.
2. The British Pharmacopoeia. Vol-I and II, London: Controller of Her Majesty’s Stationary
Office, 2009; 78-82.
3. Anonymous, www.pharmainfo.net
4. Aulton M.E. Pharmaceutics: The science of dosage form design, 3rd
edition, Churchill
Livingstone, New York, 2007; 355-359,483-498.
5. Bandhalarajan S., Shanmugam S. and Vetrichelvan T. Formulation and Evaluation of
Sustained Release Matrix Tablet of Zidovudine Using Different Polymers, Research
Journal of Pharmaceutical, Biological and Chemical Sciences, 2011; 2(1): 576-589.
6. Brahmankar D.M. and Jaiswal S.B. Biopharmaceutics and Pharmacokinetics A Treatise.
2nd
edition, Vallabh Prakashan, New Delhi, 2009; 397-452.
7. Jithan A. Oral Drug Delivery Technology, Pharma Book Syndicate, New York, 2007;
176-183.
8. Joel A. and Linbird E. Goodman & Gilman's The Pharmacological basis of Therapeutics,
10th
edition, Mc Graw Hill Medical, London, 2001; 708-710.
9. Lachman L., Lieberman H.A. and Kanig J. L. The Theory and Practice of Industrial
Pharmacy, 3rd
edition, Varghese Publishing House, Mumbai, 1991; 293-343, 430-439.
10. Lieberman H.A., Lachman L. and Schwartz J.B. Pharmaceutical Dosage Forms: Tablets
Vol-I and III, Revised and Expanded, 2nd
edition, Marcell Dekker, New York., 1999;
131-245, 199-213.
11. Shargel L. and Andrew B.C.Y. Applied Biopharmaceutics and Pharmacokinetics, 5th
edition, Singapore, 2005; 515-548.
12. Sharma A., Shweta S. and Kamal K.J. The Study of Salbutamol Matrix Tablets, Using
Different Polymers as Release Retarding Agent The Pharma Research, 2009; 1: 15-22.
13. Subramanyam C.V.S. Text Book of Physical Pharmaceutics, Vallabh Prakashan. New
Delhi, 2009; 222-228.
www.wjpr.net Vol 8, Issue 8, 2019.
Kailas et al. World Journal of Pharmaceutical Research
353
14. Suvakanta D., Narasimha M.P., Lilakanta N. and Chowdhry P. Kinetic Modeling on Drug
Release from Drug Delivery Systems, Acta Poloniae Pharmaceutical Drug Research,
2010; 67(3): 217-223.
15. Vyas S.P. and Khar R.K. Controlled Drug Delivery, Concepts and Advances, Vallabh
Prakashan, 1st edition, New Delhi, 2002; 1-36, 97-151, 164-170.
16. Vijaya Durga. K., Ashok Kumar P. and Suresh V. Kulkarni. Influence of Natural,
Synthetic Polymers and Fillers on sustained release matrix tablets of Pregabalin, Elsevier,
2013; 5(4): 252-267.
17. H.D.Zalte, R.B.Saudagar. Review on sustained release matrix tablet, IJPBS, 2013; 3(4):
17-29.
18. Jaimini Manish, Kothari Abhay. Sustained Release Matrix Type Drug Delivery System:
A Review, Journal of Drug Delivery & Therapeutics, 2012; 2(6): 142-148.